Document And Entity Information
Document And Entity Information | 9 Months Ended |
Sep. 30, 2015shares | |
Document And Entity Information [Abstract] | |
Document Type | 10-Q |
Amendment Flag | false |
Document Period End Date | Sep. 30, 2015 |
Document Fiscal Period Focus | Q3 |
Document Fiscal Year Focus | 2,015 |
Entity Registrant Name | CHEMED CORP |
Trading Symbol | CHE |
Entity Central Index Key | 19,584 |
Current Fiscal Year End Date | --12-31 |
Entity Filer Category | Large Accelerated Filer |
Entity Common Stock, Shares Outstanding | 16,879,147 |
Consolidated Balance Sheet
Consolidated Balance Sheet - USD ($) $ in Thousands | Sep. 30, 2015 | Dec. 31, 2014 |
Current assets | ||
Cash and cash equivalents | $ 38,450 | $ 14,132 |
Accounts receivable less allowances of $16,548 (2014 - $14,728) | 123,665 | 124,607 |
Inventories | 6,545 | 6,168 |
Current deferred income taxes | 17,323 | 15,414 |
Prepaid income taxes | 3,299 | 2,787 |
Prepaid expenses | 11,493 | 11,456 |
Total current assets | 200,775 | 174,564 |
Investments of deferred compensation plans | 49,951 | 49,147 |
Properties and equipment, at cost, less accumulated depreciation of $195,446 ( 2014 - $185,735) | 111,221 | 105,336 |
Identifiable intangible assets less accumulated amortization of $33,174 (2014 - $32,772) | 55,834 | 56,027 |
Goodwill | 472,407 | 466,722 |
Other assets | 7,450 | 8,136 |
Total Assets | 897,638 | 859,932 |
Current liabilities | ||
Accounts payable | 52,468 | 46,849 |
Current portion of long-term debt | 7,500 | 6,250 |
Income taxes | 736 | 5,818 |
Accrued insurance | 42,356 | 40,814 |
Accrued compensation | 59,533 | 50,718 |
Accrued legal | 1,698 | 753 |
Other current liabilities | 22,472 | 24,352 |
Total current liabilities | 186,763 | 175,554 |
Deferred income taxes | 29,370 | 29,945 |
Long-term debt | 130,625 | 141,250 |
Deferred compensation liabilities | 49,282 | 48,684 |
Other liabilities | 13,022 | 13,143 |
Total Liabilities | $ 409,062 | $ 408,576 |
Commitments and contingencies | ||
STOCKHOLDERS' EQUITY | ||
Capital stock - authorized 80,000,000 shares $1 par; issued 33,816,088 shares (2014 - 33,337,297 shares) | $ 33,816 | $ 33,337 |
Paid-in capital | 581,342 | 538,845 |
Retained earnings | 839,979 | 771,176 |
Treasury stock - 17,037,021 shares (2014 - 16,446,572) | (968,946) | (894,285) |
Deferred compensation payable in Company stock | 2,385 | 2,283 |
Total Stockholders' Equity | 488,576 | 451,356 |
Total Liabilities and Stockholders' Equity | $ 897,638 | $ 859,932 |
Consolidated Balance Sheet (Par
Consolidated Balance Sheet (Parenthetical) - USD ($) $ in Thousands | Sep. 30, 2015 | Dec. 31, 2014 |
Consolidated Balance Sheet [Abstract] | ||
Accounts receivable, allowances | $ 16,548 | $ 14,728 |
Properties and equipment, accumulated depreciation | 195,446 | 185,735 |
Identifiable intangible assets, accumulated amortization | $ 33,174 | $ 32,772 |
Capital stock - authorized | 80,000,000 | 80,000,000 |
Capital stock - par value | $ 1 | $ 1 |
Capital stock - issued | 33,816,088 | 33,337,297 |
Treasury stock | 17,037,021 | 16,446,572 |
Consolidated Statement Of Incom
Consolidated Statement Of Income - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2015 | Sep. 30, 2014 | Sep. 30, 2015 | Sep. 30, 2014 | |
Consolidated Statement Of Income [Abstract] | ||||
Service revenues and sales | $ 386,226 | $ 358,389 | $ 1,144,799 | $ 1,076,871 |
Cost of services provided and goods sold (excluding depreciation) | 272,089 | 256,445 | 811,637 | 771,271 |
Selling, general and administrative expenses | 55,197 | 53,566 | 171,779 | 162,886 |
Depreciation | 8,075 | 7,450 | 24,189 | 21,871 |
Amortization | 737 | 717 | 1,895 | 2,461 |
Total costs and expenses | 336,098 | 318,178 | 1,009,500 | 958,489 |
Income from operations | 50,128 | 40,211 | 135,299 | 118,382 |
Interest expense | (908) | (980) | (2,846) | (7,224) |
Other income/(expense) - net | (2,355) | 705 | (1,256) | 2,277 |
Income before income taxes | 46,865 | 39,936 | 131,197 | 113,435 |
Income taxes | (18,032) | (15,351) | (50,852) | (43,913) |
Net income | $ 28,833 | $ 24,585 | $ 80,345 | $ 69,522 |
Earnings Per Share | ||||
Net income | $ 1.71 | $ 1.44 | $ 4.76 | $ 4.03 |
Average number of shares outstanding | 16,865 | 17,039 | 16,887 | 17,263 |
Diluted Earnings Per Share | ||||
Net income | $ 1.65 | $ 1.39 | $ 4.61 | $ 3.87 |
Average number of shares outstanding | 17,422 | 17,627 | 17,430 | 17,968 |
Cash Dividends Per Share | $ 0.24 | $ 0.22 | $ 0.68 | $ 0.62 |
Consolidated Statement Of Cash
Consolidated Statement Of Cash Flows - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2015 | Sep. 30, 2014 | |
Cash Flows from Operating Activities | ||
Net income | $ 80,345 | $ 69,522 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||
Depreciation and amortization | 26,084 | 24,332 |
Deferred income taxes | (2,694) | 5,630 |
Provision for uncollectible accounts receivable | 11,100 | 9,573 |
Amortization of discount on convertible notes | 3,392 | |
Stock option expense | 3,600 | 3,430 |
Amortization of debt issuance costs | 392 | 697 |
Noncash long-term incentive compensation | 3,755 | 1,988 |
Changes in operating assets and liabilities, excluding amounts acquired in business combinations: | ||
Increase in accounts receivable | (10,110) | (50,027) |
Decrease/(increase) in inventories | (373) | 318 |
Decrease in prepaid expenses | 68 | 4,398 |
Increase/(decrease) in accounts payable and other current liabilities | 5,956 | (29,680) |
Increase in income taxes | 3,049 | 8,186 |
Increase in other assets | (605) | (3,138) |
Increase in other liabilities | 524 | 5,370 |
Excess tax benefit on share-based compensation | (8,474) | (3,737) |
Other sources | 467 | 755 |
Net cash provided by operating activities | 113,084 | 51,009 |
Cash Flows from Investing Activities | ||
Capital expenditures | (30,194) | (31,745) |
Business combinations, net of cash acquired | (6,614) | (250) |
Other sources | 396 | 189 |
Net cash used by investing activities | (36,412) | (31,806) |
Cash Flows from Financing Activities | ||
Proceeds from revolving line of credit | 103,200 | 308,600 |
Payments on revolving line of credit | (108,200) | (233,800) |
Payments on other long-term debt | (4,375) | (188,206) |
Proceeds from other long-term debt | 100,000 | |
Purchases of treasury stock | (36,682) | (99,103) |
Proceeds from exercise of stock options | 11,193 | 22,123 |
Dividends paid | (11,542) | (10,558) |
Capital stock surrendered to pay taxes on stock-based compensation | (11,226) | (6,121) |
Retirement of warrants | (2,645) | |
Excess tax benefit on share-based compensation | 8,474 | 3,737 |
Debt issuance costs | (939) | |
Increase/(decrease) in cash overdrafts payable | (1,745) | 22,233 |
Other uses | (1,451) | (380) |
Net cash used by financing activities | (52,354) | (85,059) |
Increase/(decrease) in cash and cash equivalents | 24,318 | (65,856) |
Cash and cash equivalents at beginning of year | 14,132 | 84,418 |
Cash and cash equivalents at end of period | $ 38,450 | $ 18,562 |
Basis Of Presentation
Basis Of Presentation | 9 Months Ended |
Sep. 30, 2015 | |
Basis Of Presentation [Abstract] | |
Basis Of Presentation | 1. Basis of Presentation As used herein, the terms "We," "Company" and "Chemed" refer to Chemed Corporation or Chemed Corporation and its consolidated subsidiaries. We have prepared the accompanying unaudited consolidated financial statements of Chemed in accordance with Rule 10-01 of SEC Regulation S-X. Consequently, we have omitted certain disclosures required under generally accepted accounting principles in the United States (“GAAP”) for complete financial statements. The December 31, 2014 balance sheet data were derived from audited financial statements but do not include all disclosures required by GAAP. However, in our opinion, the financial statements presented herein contain all adjustments, consisting only of normal recurring adjustments, necessary to state fairly our financial position, results of operations and cash flows. These financial statements are prepared on the same basis as and should be read in conjunction with the audited Consolidated Financial Statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2014. |
Revenue Recognition
Revenue Recognition | 9 Months Ended |
Sep. 30, 2015 | |
Revenue Recognition [Abstract] | |
Revenue Recognition | 2. Revenue Recognition Both the VITAS segment and the Roto-Rooter segment recognize service revenues and sales when the earnings process has been completed. Generally, this occurs when services are provided or products are delivered. VITAS recognizes revenue at the estimated realizable amount due from third-party payers. Medicare payments are subject to certain limitations, as described below. We actively monitor each of our hospice programs, by provider number, as to their specific admission, discharge rate and median length of stay data in an attempt to determine whether they are likely to exceed the annual per-beneficiary Medicare cap (“Medicare cap”). Should we determine that revenues for a program are likely to exceed the Medicare cap based on projected trends, we attempt to institute corrective action to influence the patient mix or to increase patient admissions. However, should we project our corrective action will not prevent that program from exceeding its Medicare cap, we estimate the amount of revenue recognized during the period that will require repayment to the Federal government under the Medicare cap and record the amount as a reduction to patient revenue. During the third quarter of 2015, no Medicare cap was recorded. During the first nine months ended September 30, 2015, we recorded a $ 165,000 Medicare cap reversal of amounts recorded in the fourth quarter of 2014 for one program’s projected 2015 measurement period liability. The fourth quarter of 2014 was part of the 2015 Medicare cap year. Shown below is the Medicare cap liability activity for the fiscal periods ended (in thousands): September 30, 2015 2014 Beginning balance January 1, $ $ 2015 measurement period - 2014 measurement period - Payments Ending balance September 30, $ $ Vitas provides charity care, in certain circumstances, to patients without charge when management of the hospice program determines, at the time services are performed, that the patient does not have the financial wherewithal to make payment. There is no revenue or associated accounts receivable in the accompanying consolidated financial statements related to charity care. The cost of charity care is calculated by taking the ratio of charity care days to total days of care and multiplying by total cost of care. The cost of charity care is as follows (in thousands): Three months ended September 30, Nine months ended September 30, 2015 2014 2015 2014 $ $ $ $ |
Segments
Segments | 9 Months Ended |
Sep. 30, 2015 | |
Segments [Abstract] | |
Segments | 3. Segments Service revenues and sales and after-tax earnings by business segment are as follows (in thousands): Three months ended September 30, Nine months ended September 30, 2015 2014 2015 2014 Service Revenues and Sales VITAS $ $ $ $ Roto-Rooter Total $ $ $ $ After-tax Earnings VITAS $ $ $ $ Roto-Rooter Total Corporate Net income $ $ $ $ We report corporate administrative expenses and unallocated investing and financing income and expense not directly related to either segment as “Corporate”. |
Earnings Per Share
Earnings Per Share | 9 Months Ended |
Sep. 30, 2015 | |
Earnings Per Share [Abstract] | |
Earnings Per Share | 4. Earnings per Share Earnings per share (“EPS”) are computed using the weighted average number of shares of capital stock outstanding. Earnings and diluted earnings per share are computed as follows (in thousands, except per share data): Net Income For the Three Months Ended September 30, Income Shares Earnings per Share Earnings $ $ Dilutive stock options - Nonvested stock awards - Diluted earnings $ $ Earnings $ $ Dilutive stock options - Nonvested stock awards - Conversion of notes - Diluted earnings $ $ Net Income For the Nine Months Ended September 30, Income Shares Earnings per Share Earnings $ $ Dilutive stock options - Nonvested stock awards - Diluted earnings $ $ Earnings $ $ Dilutive stock options - Nonvested stock awards - Conversion of Notes - Diluted earnings $ $ For the three and nine -month period en ded September 30, 2015 and 2014 , no stock options were excluded from the computation of diluted earnings per share because they would have been anti-dilutive. For the three and nine -months ended September 30, 2014 diluted earnings per share was impacted by the issuance of 249,000 shares of capital stock under the conversion feature of our 1.875 % Senior Convertible Notes (the “Notes”) on the May 15, 2014 maturity date. Assuming these shares were issued April 1, 2014 increases average diluted shares outstanding for the first nine months of 2014 by 1 35 ,000 shares. |
Long-Term Debt
Long-Term Debt | 9 Months Ended |
Sep. 30, 2015 | |
Long-Term Debt [Abstract] | |
Long-Term Debt | 5. Long-Term Debt On June 30, 2014, we replaced our existing credit agreement with the Third Amended and Restated Credit Agreement (“2014 Credit Agreement”). Terms of the 2014 Credit Agreement consist of a five -year, $350 million revolving credit facility and a $100 million term loan. The 2014 Credit Agreement has a floating interest rate that is currently LIBOR plus 1 13 basis points. The debt outstanding as of September 30, 2015 consists of the following: Revolver $ Term loan Total Current portion of term loan Long-term debt $ Scheduled principal payments of the term loan are as follows: $ $ The 2014 Credit Agreement contains the following quarterly financial covenants: Description Requirement Leverage Ratio (Consolidated Indebtedness/Consolidated Adj. EBITDA) < 3.50 to 1.00 Fixed Charge Coverage Ratio (Consolidated Free Cash Flow/Consolidated Fixed Charges) > 1.50 to 1.00 Annual Operating Lease Commitment < $50.0 million We are in compliance with al l debt covenants as of September 30, 2015. We have issued $36.6 million in standby le tters of credit as of September 30, 2015 for insurance purposes. Issued letters of credit reduce our available credit under the 2014 Cr edit Agreement. As of September 30, 2015, we have approximately $268.4 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility. |
Other Income_(Expense) - Net
Other Income/(Expense) - Net | 9 Months Ended |
Sep. 30, 2015 | |
Other Income/(Expense) - Net [Abstract] | |
Other Income/(Expense) - Net | 6. Other Income /(Expense) – Net Other income /(expense) -- net comprises the following (in thousands): Three months ended September 30, Nine months ended September 30, 2015 2014 2015 2014 Market value gains/(losses) on assets held in deferred compensation trust $ $ $ $ Loss on disposal of property and equipment Interest income - net Other - net Total other income/(expense) - net $ $ $ $ |
Stock-Based Compensation Plans
Stock-Based Compensation Plans | 9 Months Ended |
Sep. 30, 2015 | |
Stock-Based Compensation Plans [Abstract] | |
Stock-Based Compensation Plans | 7. Stock-Based Compensation Plans On May 18, 2015, the Compensation/Incentive Committee of the Board of Directors (“CIC”) approved a grant of 32,550 shares of restricted stock to certain key employees. The restricted shares vest ratably over three years from the date of issuance. The cumulative compensation expense related to the restricted stock award is $ 4.0 million and will be recognized over the three-year vesting period. We assumed no forfeitures in determining the cumulative compensation expense of the grant. On February 20, 2015, the (“CIC”) granted 10, 761 Performance Stock Units (“PSUs”) contingent upon the achievement of certain total shareholders return (“TSR”) targets as compared to the TSR of a group of peer companies for the three -year period ending December 31, 2017, the date at which such awards vest. The cumulative compensation cost of the TSR-based PSU award to be recorded over the three year service period is $1. 5 million. On February 20, 2015, the CIC also granted 1 0,761 PSUs contingent upon the achievement of certain earnings per share (“EPS”) targets for the three -year period ending December 31, 2017. At the end of each reporting period, the Company estimates the number of shares that it believes will ultimately be earned and records that expense over the service period of the award. We currently estimate the cumulative compensation cost of the EPS-based PSUs to be recorded over the three year service period is $1. 9 million. |
Independent Contractor Operatio
Independent Contractor Operations | 9 Months Ended |
Sep. 30, 2015 | |
Independent Contractor Operations [Abstract] | |
Independent Contractor Operations | 8. Independent Contractor Operations The Roto-Rooter segment sublicenses with 6 9 independent contractors to operate certain plumbing repair and drain cleaning businesses in lesser-populated areas of the United States and Canada. We had notes receivable from our independent contractors as of September 30, 2015 totaling $ 1. 9 million (December 31, 2014 - $ 1. 6 million). In most cases these loans are fully or partially secured by equipment owned by the contractor. The interest rates on the loans range from 0 % to 7 % per annum and the remaining terms of the loans range from 2 months to 5 years at September 30, 2015. We recorded the following from our independent contractors (in thousands): Three months ended September 30, Nine months ended September 30, 2015 2014 2015 2014 Revenues $ $ $ $ Pretax profits |
Retirement Plans
Retirement Plans | 9 Months Ended |
Sep. 30, 2015 | |
Retirement Plans [Abstract] | |
Retirement Plans | 9. Retirement Plans All of the Company’s plans that provide retirement and similar benefits are defined contribution plans. These expenses include the impact of market gains and losses on assets held in deferred compensation plans. Expenses for the Company’s pension and profit-sharing plans, excess benefit plans and other similar plans are as follows (in thousands): Three months ended September 30, Nine months ended September 30, 2015 2014 2015 2014 $ $ $ $ |
Legal And Regulatory Matters
Legal And Regulatory Matters | 9 Months Ended |
Sep. 30, 2015 | |
Legal And Regulatory Matters [Abstract] | |
Legal And Regulatory Matters | 10. Legal and Regulatory Matters The VITAS segment of the Company’s business operates in a heavily-regulated industry. As a result, the Company is subjected to inquiries and investigations by various government agencies, as well as to lawsuits, including qui tam actions. The following sections describe the various ongoing material lawsuits and investigations of which the Company is currently aware. It is not possible at this time for us to estimate either the timing or outcome of any of those matters, or whether any potential loss, or range of potential losses, is probable or estimable. Regulatory Matters and Litigation On May 2, 2013, the government filed a False Claims Act complaint against the Company and certain of its hospice-related subsidiaries in the U.S. District Court for the Western District of Missouri, United States v. VITAS Hospice Services, LLC, et al. , No. 4:13-cv-00449-BCW (the “2013 Action”). Prior to that date, the Company received various qui tam lawsuits and subpoenas from the U.S. Department of Justice and OIG that have been previously disclosed. The 2013 Action alleges that, since at least 2002, VITAS, and since 2004, the Company, submitted or caused the submission of false claims to the Medicare program by (a) billing Medicare for continuous home care services when the patients were not eligible, the services were not provided, or the medical care was inappropriate, and (b) billing Medicare for patients who were not eligible for the Medicare hospice benefit because they did not have a life expectancy of six months or less if their illnesses ran their normal course. This complaint seeks treble damages, statutory penalties, and the costs of the action, plus interest . The defendants filed a motion to dismiss on September 24, 2013. On September 30, 2014, t he Court denied the motion, except to the extent that claims were filed before July 24, 2002 . On November 13, 2014, the government filed a Second Amended Complaint. The Second Amended Complaint changed and supplemented some of the allegations, but did not otherwise expand the causes of action or the nature of the relief sought against VITAS. VITAS filed its Answer to the Second Amended Complaint on August 11, 2015. The Company is not able to reasonably estimate the probability of loss or range of loss at this time. For additional procedural history of this litigation, please refer to our prior quarterly and annual filings. The costs incurred related to U.S. v. Vitas and related regulatory matters were $1.2 million and $450,000 for the quarters ended September 30, 2015 and 2014, respectively. For the nine months ended September 30, 2015 and 2014, the net costs were $3.8 million and $1.6 million respectively. In November 2013, two shareholder derivative lawsuits were filed against the Company’s current and former directors, as well as certain of its officers, both of which are covered by the Company’s commercial insurance. On November 6, 2013, KBC Asset Management NV filed suit in the United States District Court for the District of Delaware, KBC Asset Management NV, derivatively on behalf of Chemed Corp. v. McNamara, et al. , No. 13 Civ. 1854 (LPS) (D. Del.). It sued Kevin McNamara, Joel Gemunder, Patrick Grace, Thomas Hutton, Walter Krebs, Andrea Lindell, Thomas Rice, Donald Saunders, Arthur Tucker, Jr., George Walsh III, Frank Wood, Timothy O’Toole, David Williams and Ernest Mrozek, together with the Company as nominal defendant. Plaintiff alleges that since at least 2004, Chemed, through VITAS, has submitted or caused the submission of false claims to Medicare. The suit alleges a claim for breach of fiduciary duty against the individual defendants, and seeks (a) a declaration that the individual defendants breached their fiduciary duties to the Company; (b) an order requiring those defendants to pay compensatory damages, restitution and exemplary damages, in unspecified amounts, to the Company; (c) an order directing the Company to implement new policies and procedures; and (d) costs and disbursements incurred in bringing the action, including attorneys’ fees. On November 14, 2013, Mildred A. North filed suit in the United States District Court for the Southern District of Ohio, North, derivatively on behalf of Chemed Corp. v. Kevin McNamara, el al. , No. 13 Civ. 833 (MDB) (S.D. Ohio). She sued Kevin McNamara, David Williams, Timothy O’Toole, Joel Gemunder, Patrick Grace, Walter Krebs, Andrea Lindell, Thomas Rice, Donald Saunders, George Walsh III, Frank Wood and Thomas Hutton, together with the Company as nominal defendant. Plaintiff alleges that, between February 2010 and the present, the individual defendants breached their fiduciary duties as officers and directors of Chemed by, among other things, (a) allegedly causing VITAS to submit improper and ineligible claims to Medicare and Medicaid; and (b) allegedly misrepresenting the state of Chemed’s internal controls. The suit alleges claims for breach of fiduciary duty, abuse of control and gross mismanagement against the individual defendants. The complaint also alleges unjust enrichment and insider trading against Messrs. McNamara, Williams and O’Toole. Plaintiff seeks (a) a declaration that the individual defendants breached their fiduciary duties to the Company; (b) an order requiring those defendants to pay compensatory damages, restitution and exemplary damages, in unspecified amounts, to the Company; (c) an order directing the Company to implement new policies and procedures; and (d) costs and disbursements incurred in bringing the action, including attorneys’ fees. On January 29, 2014 defendants in North filed a motion to transfer that case to Delaware under 28 U.S.C § 1404(a). On February 12, 2014, defendants in KBC filed a motion to dismiss that case pursuant to Federal Rules of Civil Procedure 23.1 and 12(b)(6). On September 19, 2014, the Ohio court granted defendants’ motion to transfer North to Delaware. Following that decision and in light of that transfer, on September 29, 2014, the Delaware court denied without prejudice defendants’ motion to dismiss KBC, and referred both cases to Magistrate Judge Burke. On October 15, 2014, Plaintiff KBC filed a motion to consolidate KBC with North . On February 2, 2015 the court granted the motion for consolidation in full, appointing Plaintiff KBC the sole lead plaintiff and its counsel, the sole lead and liaison counsel. The court ordered that both cases will proceed under the caption In re Chemed Corp. Shareholder and Derivative Litigation , No. 13 Civ. 1854 (LPS) (CJB) (D. Del.). Plaintiff KBC has designated its pending complaint as the operative complaint in the consolidated proceedings. Defendants have renewed their motion to dismiss the claims and allegations. The Company intends to defend vigorously against the allegations in each of the above lawsuits. Regardless of the outcome of any of the preceding matters, responding to the subpoenas and dealing with the various regulatory agencies and opposing parties can adversely affect us through defense costs, potential payments, diversion of management time, and related publicity. Although the Company intends to defend them vigorously, there can be no assurance that those suits will not have a material adverse effect on the Company. |
Concentration Of Risk
Concentration Of Risk | 9 Months Ended |
Sep. 30, 2015 | |
Concentration Of Risk [Abstract] | |
Concentration Of Risk | 11. Concentration of Risk VITAS has pharmacy services agreements ("Agreements") with Enclara Pharmacia (previously Hospice Pharmacia) and its subsidiaries whereby Enclara provides specified pharmacy services for VITAS and its hospice patients in geographical areas served by both VITAS and Enclara. VITAS made purchases from Enclara of $ 9.5 million and $ 8.8 million for the three months ended September 30, 2015 and 2014, respectively. VITAS made purchases from Enclara of $28.3 million and $26.5 million for the nine months ended September 30, 2015 and 2014, respectively. For the three and nine month periods ending September 30, 2015 and 2014, respectively, purchases from this vendor exceed 90 % of all pharmacy services used by VITAS. |
Cash Overdrafts And Cash Equiva
Cash Overdrafts And Cash Equivalents | 9 Months Ended |
Sep. 30, 2015 | |
Cash Overdrafts And Cash Equivalents [Abstract] | |
Cash Overdrafts And Cash Equivalents | 12. Cash Overdrafts and Cash Equivalents I ncluded in accounts payable at September 30 , 2015 is cash overdrafts payable of $ 8.8 million (December 31, 2014 - $10.5 million). From time to time throughout the year, we invest excess cash in money market funds with major commercial banks. We closely monitor the creditworthiness of the institutions with which we invest our ov ernight funds. We had $ 52 ,000 in cash equivalents as of September 30 , 2015. There was $ 80,000 in cash equivalents as of December 31, 2014. The weighted average rate of return for our cash equivalents was 0. 10 % at September 30 , 2015 and 0.06 % at December 31, 2014. |
Financial Instruments
Financial Instruments | 9 Months Ended |
Sep. 30, 2015 | |
Financial Instruments [Abstract] | |
Financial Instruments | 13. Financial Instruments FASB’s authoritative guidance on fair value measurements defines a hierarchy which prioritizes the inputs in fair value measurements. Level 1 measurements are measurements using quoted prices in active markets for identical assets or liabilities. Level 2 measurements use significant other observable inputs. Level 3 measurements are measurements using significant unobservable inputs which require a company to develop its own assumptions. In recording the fair value of assets and liabilities, companies must use the most reliable measurement available . For cash and cash equivalents, accounts receivable and accounts payable, the carrying amount is a reasonable estimate of fair value because of the liquidity and short-term nature of these instruments. The following shows the carrying value, fair value and the hierarchy for our financial instruments as of September 30, 2015 (in thousands): Fair Value Measure Carrying Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Mutual fund investments of deferred compensation plans held in trust $ $ $ - $ - Long-term debt - - For the mutual fund investments carrying value is fair value. All outstanding long-term debt is at a floating interest rate tied to LIBOR. Therefore, the carrying amount is a reasonable estimation of fair value. The following shows the carrying value, fair value and the hierarchy for our financial instruments as of December 31, 2014 (in thousands): Fair Value Measure Carrying Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Mutual fund investments of deferred compensation plans held in trust $ $ $ - $ - Long-term debt - - |
Capital Stock Repurchases Plan
Capital Stock Repurchases Plan Transactions | 9 Months Ended |
Sep. 30, 2015 | |
Capital Stock Repurchases Plan Transactions [Abstract] | |
Capital Stock Repurchases Plan Transactions | 14. Capital Stock Repurchase Plan Transactions We repurchased the following capital stock for the three and nine months ended September 30 , 2015 and 2014: Three months ended September 30, Nine months ended September 30, 2015 2014 2015 2014 Total cost of repurchased shares $ $ $ $ Shares repurchased Weighted average price per share $ $ $ $ In March 2015, the Board of Directors authorized an additional $ 100 million for stock repurchase under Chemed’s existing share repurchase program. We currently have $ 63.8 m illion of au thorization remaining under this share repurchase plan. Of the $18.2 million and $48.0 million in repurchases made during the three and nine months ended September 30, 2015 respectively, $11.3 million was paid for in October 2015. Amounts repurchased but settled subsequent to the end of the periods are considered non-cash financing activities and excluded from the Consolidated Statement of Cash Flows. |
Recent Accounting Statements
Recent Accounting Statements | 9 Months Ended |
Sep. 30, 2015 | |
Recent Accounting Statements [Abstract] | |
Recent Accounting Statements | 15. Recent Accounting Statements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update “ASU No. 2014-09 – Revenue from Contracts with Customers” which provides additional guidance to clarify the principles for recognizing revenue. The standard will also be used to develop a common revenue standard for removing inconsistencies and weaknesses, improve comparability, provide more useful information to users through improved disclosure requirements, and simplify the preparation of financial statements. The guidance is effective for fiscal years beginning after December 15, 2017. We are currently evaluating the impact of this ASU on our existing revenue recognition policies and disclosures. In August 2014, the FASB issued Accounting Standards Update No. 2014-15, “ASU No. 2014-15 - Presentation of Financial Statements-Going Concern”. ASU 2014-15 is intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. This guidance is effective for us for the annual period ending December 31, 2016 and interim periods thereafter. We do not expect the adoption of this standard to have a material impact on our consolidated financial position, result s of operations or cash flows. In April 2015, the FASB issued Accounting Standards Update No. 2015-03, “ASU No. 2015-03 – Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”. ASU 2015-03 is intended to simplify the presentation of debt issuance costs. Under the new guidance, debt issuance costs will be presented as a direct deduction from the carrying value of the associated debt, consistent with the existing presentation of a debt discount. This guidance is effective for us for the annual period beginning after December 15, 2015. We do not expect the adoption of this standard to have a material impact on our consolidated financial posi tion, results of operations or cash flows. In August 2015, the FASB issued Accounting Standards Update No. 2015-15, “ASU No. 2015-15- Interest – Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line of Credit Arrangements”. This Accounting Standards Update adds SEC paragraphs pursuant to the SEC Staff Accouncement at the June 18, 2015 Emerging Issues Task Force (EITF) meeting. Given the absence of authoritative guidance within Update 2015-03 for debt issuance costs related to line-of-credit arrangements, the SEC staff would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance ratably over the term of the line-of-credit arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. We do not expect this interpretation to have a material impact on our consolidated financial position, results of operations or cash flows. |
Business Combinations
Business Combinations | 9 Months Ended |
Sep. 30, 2015 | |
Business Combinations [Abstract] | |
Business Combinations | 16 . Business Combinations In the first nine months of 2015, we completed two business combinations within our Roto-Rooter segment for $6.6 million in cash to increase our market penetration in Omaha, Nebraska and Scranton, Pennsylvania. A substantial portion of this aggregate purchase price was allocated to goodwill. The operating results of these business combinations have been included in our results of operations since the acquisition date and are not material for the three and nine-month periods ended September 30, 2015 nor for the comparable prior year periods. Shown below is movement in Goodwill (in thousands): Vitas Roto-Rooter Total Balance at January 1, 2014 $ $ $ Business combinations - Foreign currency adjustments - Program closing - Balance at December 31, 2014 $ $ $ Business combinations - Foreign currency adjustments - Balance at September 30, 2015 $ $ $ |
Revenue Recognition (Tables)
Revenue Recognition (Tables) | 9 Months Ended |
Sep. 30, 2015 | |
Revenue Recognition [Abstract] | |
Schedule Of Medicare Cap Liability Activity | September 30, 2015 2014 Beginning balance January 1, $ $ 2015 measurement period - 2014 measurement period - Payments Ending balance September 30, $ $ |
Schedule Of Cost Of Charity Care | Three months ended September 30, Nine months ended September 30, 2015 2014 2015 2014 $ $ $ $ |
Segments (Tables)
Segments (Tables) | 9 Months Ended |
Sep. 30, 2015 | |
Segments [Abstract] | |
Service Revenues And Sales And After-Tax Earnings By Business Segment | Three months ended September 30, Nine months ended September 30, 2015 2014 2015 2014 Service Revenues and Sales VITAS $ $ $ $ Roto-Rooter Total $ $ $ $ After-tax Earnings VITAS $ $ $ $ Roto-Rooter Total Corporate Net income $ $ $ $ |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 9 Months Ended |
Sep. 30, 2015 | |
Earnings Per Share [Abstract] | |
Schedule Of Computation Of Earnings Per Share | Net Income For the Three Months Ended September 30, Income Shares Earnings per Share Earnings $ $ Dilutive stock options - Nonvested stock awards - Diluted earnings $ $ Earnings $ $ Dilutive stock options - Nonvested stock awards - Conversion of notes - Diluted earnings $ $ Net Income For the Nine Months Ended September 30, Income Shares Earnings per Share Earnings $ $ Dilutive stock options - Nonvested stock awards - Diluted earnings $ $ Earnings $ $ Dilutive stock options - Nonvested stock awards - Conversion of Notes - Diluted earnings $ $ |
Long-Term Debt (Tables)
Long-Term Debt (Tables) | 9 Months Ended |
Sep. 30, 2015 | |
Long-Term Debt [Abstract] | |
Debt Outstanding | Revolver $ Term loan Total Current portion of term loan Long-term debt $ |
Schedule of Principal Payments of the Term Loan | $ $ |
Financial Debt Covenants | Description Requirement Leverage Ratio (Consolidated Indebtedness/Consolidated Adj. EBITDA) < 3.50 to 1.00 Fixed Charge Coverage Ratio (Consolidated Free Cash Flow/Consolidated Fixed Charges) > 1.50 to 1.00 Annual Operating Lease Commitment < $50.0 million |
Other Income_(Expense) - Net (T
Other Income/(Expense) - Net (Tables) | 9 Months Ended |
Sep. 30, 2015 | |
Other Income/(Expense) - Net [Abstract] | |
Schedule Of Other Income/(expense)- Net | Three months ended September 30, Nine months ended September 30, 2015 2014 2015 2014 Market value gains/(losses) on assets held in deferred compensation trust $ $ $ $ Loss on disposal of property and equipment Interest income - net Other - net Total other income/(expense) - net $ $ $ $ |
Independent Contractor Operat27
Independent Contractor Operations (Tables) | 9 Months Ended |
Sep. 30, 2015 | |
Independent Contractor Operations [Abstract] | |
Schedule Of Independent Contractors | Three months ended September 30, Nine months ended September 30, 2015 2014 2015 2014 Revenues $ $ $ $ Pretax profits |
Retirement Plans (Tables)
Retirement Plans (Tables) | 9 Months Ended |
Sep. 30, 2015 | |
Retirement Plans [Abstract] | |
Schedule Of Expenses For Retirement, Profit-Sharing Plans, Excess Benefit Plans And Other Similar Plans | Three months ended September 30, Nine months ended September 30, 2015 2014 2015 2014 $ $ $ $ |
Financial Instruments (Tables)
Financial Instruments (Tables) | 9 Months Ended |
Sep. 30, 2015 | |
Financial Instruments [Abstract] | |
Carrying Value, Fair Value And Hierarchy Of Financial Instruments | The following shows the carrying value, fair value and the hierarchy for our financial instruments as of September 30, 2015 (in thousands): Fair Value Measure Carrying Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Mutual fund investments of deferred compensation plans held in trust $ $ $ - $ - Long-term debt - - For the mutual fund investments carrying value is fair value. All outstanding long-term debt is at a floating interest rate tied to LIBOR. Therefore, the carrying amount is a reasonable estimation of fair value. The following shows the carrying value, fair value and the hierarchy for our financial instruments as of December 31, 2014 (in thousands): Fair Value Measure Carrying Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Mutual fund investments of deferred compensation plans held in trust $ $ $ - $ - Long-term debt - - |
Capital Stock Repurchase Plan T
Capital Stock Repurchase Plan Transactions (Tables) | 9 Months Ended |
Sep. 30, 2015 | |
Capital Stock Repurchases Plan Transactions [Abstract] | |
Schedule Of Capital Stock Repurchases | Three months ended September 30, Nine months ended September 30, 2015 2014 2015 2014 Total cost of repurchased shares $ $ $ $ Shares repurchased Weighted average price per share $ $ $ $ |
Business Combinations (Tables)
Business Combinations (Tables) | 9 Months Ended |
Sep. 30, 2015 | |
Business Combinations [Abstract] | |
Schedule of movement in Goodwill | Vitas Roto-Rooter Total Balance at January 1, 2014 $ $ $ Business combinations - Foreign currency adjustments - Program closing - Balance at December 31, 2014 $ $ $ Business combinations - Foreign currency adjustments - Balance at September 30, 2015 $ $ $ |
Revenue Recognition (Narrative)
Revenue Recognition (Narrative) (Details) - USD ($) | 3 Months Ended | 9 Months Ended |
Sep. 30, 2015 | Sep. 30, 2015 | |
Revenue Recognition [Abstract] | ||
Medicare cap reversal | $ 0 | $ 165,000 |
Revenue Recognition (Schedule O
Revenue Recognition (Schedule Of Medicare Cap Liability Activity) (Details) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2015 | Sep. 30, 2014 | |
Revenue Recognition [Abstract] | ||
Beginning Balance January 1, | $ 6,112 | $ 8,260 |
2015 measurement period | (165) | |
2014 measurement period | 1,796 | |
Payments | (4,782) | (3,439) |
Ending Balance September 30, | $ 1,165 | $ 6,617 |
Revenue Recognition (Schedule34
Revenue Recognition (Schedule Of Cost Of Charity Care) (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2015 | Sep. 30, 2014 | Sep. 30, 2015 | Sep. 30, 2014 | |
Revenue Recognition [Abstract] | ||||
Charity care cost | $ 1,929 | $ 1,827 | $ 5,788 | $ 5,518 |
Segments (Service Revenues And
Segments (Service Revenues And Sales And After-Tax Earnings By Business Segment) (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2015 | Sep. 30, 2014 | Sep. 30, 2015 | Sep. 30, 2014 | |
Segment Reporting Information [Line Items] | ||||
Total service revenues and sales | $ 386,226 | $ 358,389 | $ 1,144,799 | $ 1,076,871 |
Net income | 28,833 | 24,585 | 80,345 | 69,522 |
Operating Segments [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Total service revenues and sales | 386,226 | 358,389 | 1,144,799 | 1,076,871 |
Net income | 36,684 | 31,441 | 101,961 | 91,244 |
Corporate Segment [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Net income | (7,851) | (6,856) | (21,616) | (21,722) |
Segment VITAS [Member] | Operating Segments [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Total service revenues and sales | 285,008 | 265,384 | 831,081 | 789,822 |
Net income | 25,723 | 21,593 | 66,839 | 60,645 |
Segment Roto-Rooter [Member] | Operating Segments [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Total service revenues and sales | 101,218 | 93,005 | 313,718 | 287,049 |
Net income | $ 10,961 | $ 9,848 | $ 35,122 | $ 30,599 |
Earnings Per Share (Narrative)
Earnings Per Share (Narrative) (Details) | 3 Months Ended | 9 Months Ended |
Sep. 30, 2014shares | Sep. 30, 2014shares | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Shares issued in conjunction with the conversion feature of the Notes | 249,000 | 249,000 |
Dilutive impact of the warrants | 135,000 | |
Senior Convertible Notes [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Interest rate of senior convertible notes | 1.875% | 1.875% |
Earnings Per Share (Schedule Of
Earnings Per Share (Schedule Of Computation Of Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2015 | Sep. 30, 2014 | Sep. 30, 2015 | Sep. 30, 2014 | |
Earnings Per Share [Abstract] | ||||
Earnings, Income | $ 28,833 | $ 24,585 | $ 80,345 | $ 69,522 |
Diluted earnings, Income | $ 28,833 | $ 24,585 | $ 80,345 | $ 69,522 |
Earnings per Share | $ 1.71 | $ 1.44 | $ 4.76 | $ 4.03 |
Earnings per Share, Diluted | $ 1.65 | $ 1.39 | $ 4.61 | $ 3.87 |
Net Income, Earnings, Shares | 16,865 | 17,039 | 16,887 | 17,263 |
Dilutive stock options, Shares | 399 | 416 | 391 | 402 |
Nonvested stock awards, Shares | 158 | 151 | 152 | 147 |
Conversion of Notes, Shares | 21 | 156 | ||
Net Income, Diluted Earnings, Shares | 17,422 | 17,627 | 17,430 | 17,968 |
Long-Term Debt (Narrative) (Det
Long-Term Debt (Narrative) (Details) | 9 Months Ended |
Sep. 30, 2015USD ($) | |
Debt Instrument [Line Items] | |
Standby letters of credit issued | $ 36,600,000 |
Revolving Credit Facility [Member] | |
Debt Instrument [Line Items] | |
Unused lines of credit | $ 268,400,000 |
2014 Credit Agreement [Member] | |
Debt Instrument [Line Items] | |
Debt instrument term | 5 years |
2014 Credit Agreement [Member] | LIBOR [Member] | |
Debt Instrument [Line Items] | |
Basis spread on variable interest rate | 1.13% |
2014 Credit Agreement [Member] | Revolving Credit Facility [Member] | |
Debt Instrument [Line Items] | |
Face amount of debt | $ 350,000,000 |
2014 Credit Agreement [Member] | Medium-term Notes [Member] | |
Debt Instrument [Line Items] | |
Face amount of debt | $ 100,000,000 |
Long-Term Debt (Debt Outstandin
Long-Term Debt (Debt Outstanding) (Details) - USD ($) $ in Thousands | Sep. 30, 2015 | Dec. 31, 2014 |
Debt Instrument [Line Items] | ||
Total | $ 138,125 | |
Current portion of term loan | (7,500) | $ (6,250) |
Long-term debt | 130,625 | $ 141,250 |
Revolving Credit Facility [Member] | ||
Debt Instrument [Line Items] | ||
Total | 45,000 | |
Medium-term Notes [Member] | ||
Debt Instrument [Line Items] | ||
Total | $ 93,125 |
Long-Term Debt (Schedule of Pri
Long-Term Debt (Schedule of Principal Payments of the Term Loan) (Details) $ in Thousands | Sep. 30, 2015USD ($) |
Debt Instrument [Line Items] | |
Total | $ 138,125 |
Medium-term Notes [Member] | |
Debt Instrument [Line Items] | |
2,015 | 1,875 |
2,016 | 7,500 |
2,017 | 8,750 |
2,018 | 10,000 |
2,019 | 65,000 |
Total | $ 93,125 |
Long-Term Debt (Financial Debt
Long-Term Debt (Financial Debt Covenants) (Details) $ in Millions | 9 Months Ended |
Sep. 30, 2015USD ($) | |
Long-Term Debt [Abstract] | |
Leverage Ratio (Consolidated Indebtedness/Consolidated Adj. EBITDA), Requirement | 3.50 |
Fixed Charge Coverage Ratio (Consolidated Free Cash Flow/Consolidated Fixed Charges), Requirement | 1.50 |
Annual Operating Lease Commitment, Requirement | $ 50 |
Other Income_(Expense) - Net (S
Other Income/(Expense) - Net (Schedule Of Other Income - Net) (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2015 | Sep. 30, 2014 | Sep. 30, 2015 | Sep. 30, 2014 | |
Other Income/(Expense) - Net [Abstract] | ||||
Market value gains/(losses) on assets held in deferred compensation trust | $ (2,328) | $ 896 | $ (880) | $ 2,708 |
Loss on disposal of property and equipment | (116) | (167) | (131) | (493) |
Interest income - net | 77 | (13) | 207 | (5) |
Other - net | 12 | (11) | (452) | 67 |
Total other income/(expense) - net | $ (2,355) | $ 705 | $ (1,256) | $ 2,277 |
Stock-Based Compensation Plans
Stock-Based Compensation Plans (Narrative) (Details) - USD ($) $ in Thousands | May. 18, 2015 | Feb. 20, 2015 | Sep. 30, 2015 |
Restricted Stock [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Shares vesting period, years | 3 years | ||
Stock Awards Granted | 32,550 | ||
Cumulative compensation expense | $ 4,000 | ||
Forfeitures | $ 0 | ||
Performance Based TSR [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Shares vesting period, years | 3 years | ||
Stock Awards Granted | 10,761 | ||
Cumulative compensation expense | $ 1,500 | ||
Performance Based EPS [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Shares vesting period, years | 3 years | ||
Stock Awards Granted | 10,761 | ||
Cumulative compensation expense | $ 1,900 |
Independent Contractor Operat44
Independent Contractor Operations (Narrative) (Details) $ in Millions | 9 Months Ended | |
Sep. 30, 2015USD ($)item | Dec. 31, 2014USD ($) | |
Independent Contractor Operations [Line Items] | ||
Notes receivable from independent contractors | $ | $ 1.9 | $ 1.6 |
Roto-Rooter segment [Member] | ||
Independent Contractor Operations [Line Items] | ||
Independent contractors with sublicenses | 69 | |
Maximum [Member] | ||
Independent Contractor Operations [Line Items] | ||
Interest rates on loans | 7.00% | |
Terms of the loans to independent contractors, years | 5 years | |
Minimum [Member] | ||
Independent Contractor Operations [Line Items] | ||
Interest rates on loans | 0.00% | |
Terms of the loans to independent contractors, years | 2 months |
Independent Contractor Operat45
Independent Contractor Operations (Schedule Of Independent Contractors) (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2015 | Sep. 30, 2014 | Sep. 30, 2015 | Sep. 30, 2014 | |
Independent Contractor Operations [Abstract] | ||||
Revenues | $ 9,119 | $ 8,751 | $ 28,110 | $ 26,964 |
Pretax profits | $ 5,435 | $ 4,946 | $ 16,653 | $ 15,341 |
Retirement Plans (Schedule Of E
Retirement Plans (Schedule Of Expenses For Retirement, Profit-Sharing Plans, Excess Benefit Plans And Other Similar Plans) (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2015 | Sep. 30, 2014 | Sep. 30, 2015 | Sep. 30, 2014 | |
Retirement Plans [Abstract] | ||||
Defined contribution plans expense | $ 458 | $ 3,635 | $ 7,636 | $ 10,856 |
Legal And Regulatory Matters (D
Legal And Regulatory Matters (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2015 | Sep. 30, 2014 | Sep. 30, 2015 | Sep. 30, 2014 | |
U.S. v. VITAS [Member] | ||||
Loss Contingencies [Line Items] | ||||
Net (costs) credit incurred | $ 1,200,000 | $ 450,000 | $ 3,800,000 | $ 1,600,000 |
Concentration Of Risk (Details)
Concentration Of Risk (Details) - Segment VITAS [Member] - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2015 | Sep. 30, 2014 | Sep. 30, 2015 | Sep. 30, 2014 | |
Concentration Risk [Line Items] | ||||
VITAS made purchases from Enclara | $ 9.5 | $ 8.8 | $ 28.3 | $ 26.5 |
Pharmacy Services [Member] | ||||
Concentration Risk [Line Items] | ||||
Percentage of concentration risk services represent from vendor | 90.00% | 90.00% | 90.00% | 90.00% |
Cash Overdrafts And Cash Equi49
Cash Overdrafts And Cash Equivalents (Details) - USD ($) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2015 | Dec. 31, 2014 | |
Cash Overdrafts And Cash Equivalents [Abstract] | ||
Cash overdrafts included in accounts payable | $ 8,800,000 | $ 10,500,000 |
Cash equivalents | $ 52,000 | $ 80,000 |
Cash equivalents weighted average rate of return | 0.10% | 0.06% |
Financial Instruments (Carrying
Financial Instruments (Carrying Value, Fair Value And Hierarchy Of Financial Instruments) (Details) - USD ($) $ in Thousands | Sep. 30, 2015 | Dec. 31, 2014 |
Carrying Value [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Mutual fund investments of deferred compensation plans held in trust | $ 49,951 | $ 49,147 |
Long-term debt | 138,125 | 147,500 |
Quoted Prices In Active Markets For Identical Assets (Level 1) [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Mutual fund investments of deferred compensation plans held in trust | 49,951 | 49,147 |
Significant Other Observable Inputs (Level 2) [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Long-term debt | $ 138,125 | $ 147,500 |
Capital Stock Repurchase Plan51
Capital Stock Repurchase Plan Transactions (Narrative) (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | |||
Oct. 31, 2015 | Sep. 30, 2015 | Sep. 30, 2014 | Sep. 30, 2015 | Sep. 30, 2014 | Mar. 31, 2015 | |
Equity, Class of Treasury Stock [Line Items] | ||||||
Purchases of treasury stock | $ 18,230 | $ 40,610 | $ 47,992 | $ 99,103 | ||
Stock repurchase program, amount authorized | $ 100,000 | |||||
Stock Repurchase Program, Remaining Authorized Repurchase Amount | $ 63,800 | $ 63,800 | ||||
Subsequent Event [Member] | ||||||
Equity, Class of Treasury Stock [Line Items] | ||||||
Purchases of treasury stock | $ 11,300 |
Capital Stock Repurchase Plan52
Capital Stock Repurchase Plan Transactions (Schedule Of Capital Stock Repurchases) (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2015 | Sep. 30, 2014 | Sep. 30, 2015 | Sep. 30, 2014 | |
Capital Stock Repurchases Plan Transactions [Abstract] | ||||
Total cost of repurchased shares | $ 18,230 | $ 40,610 | $ 47,992 | $ 99,103 |
Shares repurchased | 135,765 | 400,000 | 385,765 | 1,082,934 |
Weighted average price per share | $ 134.28 | $ 101.53 | $ 124.41 | $ 91.51 |
Business Combinations (Narrativ
Business Combinations (Narrative) (Details) $ in Thousands | 9 Months Ended | |
Sep. 30, 2015USD ($)item | Sep. 30, 2014USD ($) | |
Business Acquisition [Line Items] | ||
Business combinations | $ | $ 6,614 | $ 250 |
Segment Roto-Rooter [Member] | ||
Business Acquisition [Line Items] | ||
Number of Business Combinations | 2 |
Business Combinations (Schedule
Business Combinations (Schedule of movement in Goodwill) (Details) - USD ($) $ in Thousands | 9 Months Ended | 12 Months Ended |
Sep. 30, 2015 | Dec. 31, 2014 | |
Business Combination Segment Allocation [Line Items] | ||
Beginning Balance | $ 466,722 | $ 466,871 |
Foreign currency adjustments | (259) | (198) |
Business combinations | 5,944 | 198 |
Program closing | (149) | |
Ending Balance | 472,407 | 466,722 |
Segment VITAS [Member] | ||
Business Combination Segment Allocation [Line Items] | ||
Beginning Balance | 328,301 | 328,450 |
Program closing | (149) | |
Ending Balance | 328,301 | 328,301 |
Roto-Rooter segment [Member] | ||
Business Combination Segment Allocation [Line Items] | ||
Beginning Balance | 138,421 | 138,421 |
Foreign currency adjustments | (259) | (198) |
Business combinations | 5,944 | 198 |
Ending Balance | $ 144,106 | $ 138,421 |